BlueWind Medical announced it has secured $47.8 million in financing through a combination of equity and debt to accelerate commercialization of its Revi System, an Implantable Tibial Neuromodulation (ITNM) therapy designed to treat urgency urinary incontinence (UUI).
The company said the funding will support continued commercialization efforts for the Revi System, including expanding its commercial sales organization and investing further in market access initiatives aimed at increasing patient and provider access to the therapy.
BlueWind Medical said the financing follows a series of clinical milestones achieved over the past year, including three-year results from the pivotal OASIS study. According to the company, the study demonstrated sustained efficacy, strong safety outcomes, and 95% patient satisfaction at 36 months.
The Revi System is designed as an Implantable Tibial Neuromodulation device for treating urgency urinary incontinence. The device is implanted near the ankle during an outpatient procedure under local anesthesia and delivers stimulation to the posterior tibial nerve through an external wearable component. Patients activate the therapy daily at home, and the system avoids the use of internal batteries or leads.
KEY QUOTES:
“Urgency urinary incontinence affects millions of people, creating a significant need for effective, durable treatment options that fit seamlessly into patients’ lives. This financing reflects deep conviction in our team, our technology, and the opportunity ahead to establish Revi as the new standard of care.”
Kerry Nelson, Chief Executive Officer, BlueWind Medical
“This financing is an important milestone for BlueWind and a strong validation of the progress we are making as a leader in Implantable Tibial Neuromodulation for urgency urinary incontinence. The capital allows us to scale our commercial organization, expand market access, and ensure that more patients and providers can benefit from a clinically proven, patient-centric therapy. We are grateful for the continued confidence of our investors as we execute on the next phase of our growth.”
Stephen Armstrong, Chief Financial Officer, BlueWind Medical
